-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 15, the official website of the State Food and Drug Administration showed that the supplementary application of Pemetrexed Disodium for Injection by Shandong New Times Pharmaceutical was approved
October 15, 2021 drug approval document pending information release
Data show that pemetrexed is a multi-target anti-cancer folate antagonist, which inhibits cell replication by disrupting the key folate-dependent metabolic process necessary for cell replication
Sales of Pemetrexed Disodium for Terminal Injection in Public Medical Institutions in China in Recent Years
Source: Terminal competition landscape of China's public medical institutions
Pemetrexed was developed by Eli Lilly and was imported and marketed in China in 2006
Source: One-click search on Mi Nei.
There are more than 20 manufacturers of pemetrexed disodium for injection.
Up to now, Shandong New Times Pharmaceutical has been evaluated in 14 varieties (18 product specifications), of which anti-tumor and immunomodulators are the most, including 5 axitinib tablets and epirubicin hydrochloride injection.
Source: official website of the State Food and Drug Administration, Mi Nei.